chronic lymphocytic leukemia

Showing NaN - NaN of 48

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in United States (drug, other, biological)

Active, not recruiting
  • Anemia
  • +2 more
  • Birmingham, Alabama
  • +795 more
Jan 28, 2023

Acute Lymphoblastic Leukemia, Adult B-Cell, Chronic Lymphocytic Leukemia, Multiple Myeloma Trial in United States (clonoSEQ

Recruiting
  • Acute Lymphoblastic Leukemia, Adult B-Cell
  • +3 more
  • clonoSEQ Assay
  • Stanford, California
  • +15 more
Jan 30, 2023

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in United States (Ublituximab, Umbralisib, Venetoclax)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Birmingham, Alabama
  • +49 more
Jan 20, 2023

Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma Trial in United States (Zilovertamab vedotin)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • +11 more
  • Zilovertamab vedotin
  • Duarte, California
  • +13 more
Jan 12, 2023

SARS-CoV-2 Vaccines in Chronic Lymphocytic Leukemia or Small

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Biospecimen Collection
  • Electronic Health Record Review
  • Duarte, California
  • +10 more
Jan 12, 2023

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute

Active, not recruiting
  • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +13 more
  • CMVpp65-A*0201 peptide vaccine
  • +2 more
  • Duarte, California
  • +4 more
Jan 4, 2023

Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia Trial in Worldwide (Iopofosine I 131 single dose,

Recruiting
  • Waldenstrom Macroglobulinemia
  • +8 more
  • Iopofosine I 131 single dose
  • +2 more
  • Redlands, California
  • +42 more
Dec 30, 2022

Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Trial in Aurora, Seattle (drug, procedure,

Active, not recruiting
  • Acute Biphenotypic Leukemia
  • +18 more
  • Aurora, Colorado
  • +2 more
Dec 28, 2022

Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma Trial in Seattle (Allogeneic Hematopoietic

Recruiting
  • Acute Lymphoblastic Leukemia
  • +16 more
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +4 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Dec 1, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome Trial in Italy, United Kingdom, United States

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • +3 more
  • Boston, Massachusetts
  • +11 more
Nov 23, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Canada, United States (biological, other, drug)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Obinutuzumab
  • +3 more
  • Birmingham, Alabama
  • +484 more
Aug 24, 2022

Chronic Lymphocytic Leukemia Trial in Worldwide (Obinutuzumab, Ublituximab, TGR-1202)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Obinutuzumab
  • +3 more
  • Huntsville, Alabama
  • +153 more
Aug 19, 2022

Relapsed Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia Trial in Poland, United

Recruiting
  • Relapsed Non Hodgkin Lymphoma
  • +6 more
  • Cincinnati, Ohio
  • +4 more
Aug 3, 2022

Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma Trial in United States (TGR-1202, TGR-1202 + Ublituximab)

Terminated
  • Chronic Lymphocytic Leukemia
  • Non Hodgkin Lymphoma
  • Huntsville, Alabama
  • +16 more
Jul 20, 2022

Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma Trial in Worldwide (GEN3009, Epcoritamab)

Recruiting
  • Diffuse Large B-cell Lymphoma
  • +7 more
  • GEN3009
  • Epcoritamab
  • Tucson, Arizona
  • +31 more
Jul 1, 2022

Lymphoma, B-Cell, Chronic Lymphocytic Leukemia Trial in United States (FT596, Cyclophosphamide, Fludarabine)

Recruiting
  • Lymphoma, B-Cell
  • Chronic Lymphocytic Leukemia
  • Chicago, Illinois
  • +8 more
Jun 21, 2022

Chronic Lymphocytic Leukemia Trial in Israel, United States (Ublituximab, Ibrutinib)

Completed
  • Chronic Lymphocytic Leukemia
  • Huntsville, Alabama
  • +87 more
Apr 25, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma Trial in Worldwide (Ibrutinib)

Enrolling by invitation
  • Chronic Lymphocytic Leukemia
  • +6 more
  • Duarte, California
  • +165 more
Mar 24, 2022

Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma Trial in Australia, United States (ABT-199)

Completed
  • Chronic Lymphocytic Leukemia
  • Non-Hodgkin Lymphoma
  • Tucson, Arizona
  • +9 more
Feb 10, 2022

Non-hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in United States (ZX-101A)

Recruiting
  • Non-hodgkin Lymphoma
  • +2 more
  • Gilbert, Arizona
  • +5 more
Jan 14, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Worldwide (Zanubrutinib, Ibrutinib)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Little Rock, Arkansas
  • +144 more
Dec 3, 2021

B-cell Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia Trial in France, United States (XmAb13676)

Recruiting
  • B-cell Non-Hodgkins Lymphoma
  • Chronic Lymphocytic Leukemia
  • XmAb13676
  • La Jolla, California
  • +21 more
Oct 20, 2021

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Worldwide (Post-Chlorambucil Therapy Follow-up, Ibrutinib,

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Post-Chlorambucil Therapy Follow-up
  • +4 more
  • Duarte, California
  • +106 more
Aug 6, 2021

Chronic Lymphocytic Leukemia, Peripheral T-cell Lymphoma Trial in United States (20 mg/kg TRU-016 + Rituximab, 10 mg/kg TRU-016

Terminated
  • Chronic Lymphocytic Leukemia
  • Peripheral T-cell Lymphoma
  • 20 mg/kg TRU-016 + Rituximab
  • +5 more
  • Augusta, Georgia
  • +7 more
May 18, 2021